Naturally occurring carboxypeptidase A6 mutations: Effect on enzyme function and association with epilepsy

Matthew R. Sapio, Annick Salzmann, Monique Vessaz, Arielle Crespel, Peter J. Lyons, Alain Malafosse, Lloyd D. Fricker

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Carboxypeptidase A6 (CPA6) is a member of the A/B subfamily of M14 metallocarboxypeptidases that is expressed in brain and many other tissues during development. Recently, two mutations in human CPA6 were associated with febrile seizures and/or temporal lobe epilepsy. In this study we screened for additional CPA6 mutations in patients with febrile seizures and focal epilepsy, which encompasses the temporal lobe epilepsy subtype. Mutations found from this analysis as well as CPA6 mutations reported in databases of single nucleotide polymorphisms were further screened by analysis of the modeled proCPA6 protein structure and the functional role of the mutated amino acid. The point mutations predicted to affect activity and/or protein folding were tested by expression of the mutant in HEK293 cells and analysis of the resulting CPA6 protein. Common polymorphisms in CPA6 were also included in this analysis. Several mutations resulted in reduced enzyme activity or CPA6 protein levels in the extracellular matrix. The mutants with reduced extracellular CPA6 protein levels showed normal levels of 50-kDa proCPA6 in the cell, and this could be converted into 37-kDa CPA6 by trypsin, suggesting that protein folding was not greatly affected by the mutations. Interestingly, three of the mutations that reduced extracellular CPA6 protein levels were found in patients with epilepsy. Taken together, these results provide further evidence for the involvement of CPA6 mutations in human epilepsy and reveal additional rare mutations that inactivate CPA6 and could, therefore, also be associated with epileptic phenotypes.

Original languageEnglish (US)
Pages (from-to)42900-42909
Number of pages10
JournalJournal of Biological Chemistry
Volume287
Issue number51
DOIs
StatePublished - Dec 14 2012

Fingerprint

Carboxypeptidases
Epilepsy
Association reactions
Mutation
Enzymes
Protein folding
Febrile Seizures
Temporal Lobe Epilepsy
Protein Folding
Proteins
Polymorphism
Partial Epilepsy
HEK293 Cells
Enzyme activity
Point Mutation
Trypsin
Single Nucleotide Polymorphism
Extracellular Matrix
Brain
Nucleotides

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Naturally occurring carboxypeptidase A6 mutations : Effect on enzyme function and association with epilepsy. / Sapio, Matthew R.; Salzmann, Annick; Vessaz, Monique; Crespel, Arielle; Lyons, Peter J.; Malafosse, Alain; Fricker, Lloyd D.

In: Journal of Biological Chemistry, Vol. 287, No. 51, 14.12.2012, p. 42900-42909.

Research output: Contribution to journalArticle

Sapio, Matthew R. ; Salzmann, Annick ; Vessaz, Monique ; Crespel, Arielle ; Lyons, Peter J. ; Malafosse, Alain ; Fricker, Lloyd D. / Naturally occurring carboxypeptidase A6 mutations : Effect on enzyme function and association with epilepsy. In: Journal of Biological Chemistry. 2012 ; Vol. 287, No. 51. pp. 42900-42909.
@article{172355f2243a4fb690db03fa3a84a7d1,
title = "Naturally occurring carboxypeptidase A6 mutations: Effect on enzyme function and association with epilepsy",
abstract = "Carboxypeptidase A6 (CPA6) is a member of the A/B subfamily of M14 metallocarboxypeptidases that is expressed in brain and many other tissues during development. Recently, two mutations in human CPA6 were associated with febrile seizures and/or temporal lobe epilepsy. In this study we screened for additional CPA6 mutations in patients with febrile seizures and focal epilepsy, which encompasses the temporal lobe epilepsy subtype. Mutations found from this analysis as well as CPA6 mutations reported in databases of single nucleotide polymorphisms were further screened by analysis of the modeled proCPA6 protein structure and the functional role of the mutated amino acid. The point mutations predicted to affect activity and/or protein folding were tested by expression of the mutant in HEK293 cells and analysis of the resulting CPA6 protein. Common polymorphisms in CPA6 were also included in this analysis. Several mutations resulted in reduced enzyme activity or CPA6 protein levels in the extracellular matrix. The mutants with reduced extracellular CPA6 protein levels showed normal levels of 50-kDa proCPA6 in the cell, and this could be converted into 37-kDa CPA6 by trypsin, suggesting that protein folding was not greatly affected by the mutations. Interestingly, three of the mutations that reduced extracellular CPA6 protein levels were found in patients with epilepsy. Taken together, these results provide further evidence for the involvement of CPA6 mutations in human epilepsy and reveal additional rare mutations that inactivate CPA6 and could, therefore, also be associated with epileptic phenotypes.",
author = "Sapio, {Matthew R.} and Annick Salzmann and Monique Vessaz and Arielle Crespel and Lyons, {Peter J.} and Alain Malafosse and Fricker, {Lloyd D.}",
year = "2012",
month = "12",
day = "14",
doi = "10.1074/jbc.M112.414094",
language = "English (US)",
volume = "287",
pages = "42900--42909",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "51",

}

TY - JOUR

T1 - Naturally occurring carboxypeptidase A6 mutations

T2 - Effect on enzyme function and association with epilepsy

AU - Sapio, Matthew R.

AU - Salzmann, Annick

AU - Vessaz, Monique

AU - Crespel, Arielle

AU - Lyons, Peter J.

AU - Malafosse, Alain

AU - Fricker, Lloyd D.

PY - 2012/12/14

Y1 - 2012/12/14

N2 - Carboxypeptidase A6 (CPA6) is a member of the A/B subfamily of M14 metallocarboxypeptidases that is expressed in brain and many other tissues during development. Recently, two mutations in human CPA6 were associated with febrile seizures and/or temporal lobe epilepsy. In this study we screened for additional CPA6 mutations in patients with febrile seizures and focal epilepsy, which encompasses the temporal lobe epilepsy subtype. Mutations found from this analysis as well as CPA6 mutations reported in databases of single nucleotide polymorphisms were further screened by analysis of the modeled proCPA6 protein structure and the functional role of the mutated amino acid. The point mutations predicted to affect activity and/or protein folding were tested by expression of the mutant in HEK293 cells and analysis of the resulting CPA6 protein. Common polymorphisms in CPA6 were also included in this analysis. Several mutations resulted in reduced enzyme activity or CPA6 protein levels in the extracellular matrix. The mutants with reduced extracellular CPA6 protein levels showed normal levels of 50-kDa proCPA6 in the cell, and this could be converted into 37-kDa CPA6 by trypsin, suggesting that protein folding was not greatly affected by the mutations. Interestingly, three of the mutations that reduced extracellular CPA6 protein levels were found in patients with epilepsy. Taken together, these results provide further evidence for the involvement of CPA6 mutations in human epilepsy and reveal additional rare mutations that inactivate CPA6 and could, therefore, also be associated with epileptic phenotypes.

AB - Carboxypeptidase A6 (CPA6) is a member of the A/B subfamily of M14 metallocarboxypeptidases that is expressed in brain and many other tissues during development. Recently, two mutations in human CPA6 were associated with febrile seizures and/or temporal lobe epilepsy. In this study we screened for additional CPA6 mutations in patients with febrile seizures and focal epilepsy, which encompasses the temporal lobe epilepsy subtype. Mutations found from this analysis as well as CPA6 mutations reported in databases of single nucleotide polymorphisms were further screened by analysis of the modeled proCPA6 protein structure and the functional role of the mutated amino acid. The point mutations predicted to affect activity and/or protein folding were tested by expression of the mutant in HEK293 cells and analysis of the resulting CPA6 protein. Common polymorphisms in CPA6 were also included in this analysis. Several mutations resulted in reduced enzyme activity or CPA6 protein levels in the extracellular matrix. The mutants with reduced extracellular CPA6 protein levels showed normal levels of 50-kDa proCPA6 in the cell, and this could be converted into 37-kDa CPA6 by trypsin, suggesting that protein folding was not greatly affected by the mutations. Interestingly, three of the mutations that reduced extracellular CPA6 protein levels were found in patients with epilepsy. Taken together, these results provide further evidence for the involvement of CPA6 mutations in human epilepsy and reveal additional rare mutations that inactivate CPA6 and could, therefore, also be associated with epileptic phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=84871139031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871139031&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.414094

DO - 10.1074/jbc.M112.414094

M3 - Article

C2 - 23105115

AN - SCOPUS:84871139031

VL - 287

SP - 42900

EP - 42909

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 51

ER -